You are here

  • Home
  • Archive
  • Volume 10, Issue 3
  • MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer

 

Online download statistics by month:

Online download statistics by month: March 2022 to March 2026

AbstractFullPdf
Mar 202211881238283
Apr 202210971136257
May 2022656699220
Jun 202229830588
Jul 202223024477
Aug 202223424860
Sep 2022213223272
Oct 202217718775
Nov 202215916347
Dec 202214915355
Jan 202317217247
Feb 202318818881
Mar 202312012468
Apr 2023959545
May 2023929237
Jun 202310310543
Jul 2023989850
Aug 2023959533
Sep 2023949635
Oct 2023747542
Nov 202312913137
Dec 202312212362
Jan 2024575735
Feb 2024798061
Mar 202411712290
Apr 202421821842
May 202410910857
Jun 202410410543
Jul 202411912157
Aug 2024697135
Sep 202491923651
Oct 202496962154
Nov 2024687237
Dec 202410610752
Jan 202513013166
Feb 202527827863
Mar 2025989774
Apr 2025898944
May 202519119157
Jun 2025545435
Mar 2026100
Total785780798667